Results 201 to 210 of about 13,385,088 (307)

Culture and Adaptation of Pseudomonas aeruginosa During Early Infection in Children With Cystic Fibrosis. [PDF]

J Infect Dis
Mitra SD, Soneji M, Axline CMR, Hayden HS, Radey MC, Forsberg CM, Ozer EA, Wolter DJ, Pope CE, Burns J, Hoffman LR, Mayer-Hamblett N, Singh P, Hauser AR.   +13 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Evaluation of HLA Region-Specific High-Throughput Sequencing FASTQ Reads Combined with Ensemble HLA-Typing Tools for Rapid and High-Confidence HLA Typing. [PDF]

Biology (Basel)
Padul VG, Gill M, Perez JA, Lopez JJ, Kesari S, Ashili S.   +5 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Identification and management of the backup donor: recommendations from the World Marrow Donor Association. [PDF]

Bone Marrow Transplant
Greco-Stewart V, Manor S, Pollichieni S, Kathke A, Rall G, Evseeva I, Johnson P, Martfeld A, Schuit M, Tistl I.   +9 more
europepmc   +1 more source

Airline Types

, 2022
openaire   +2 more sources

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source

Anti-HLA antibodies in lung transplantation: diagnostic pitfalls and future directions. [PDF]

Eur Respir Rev
Zajacova A, Revilla-Lopez E, Guney M, De Pelsmaeker S, Emonds MP, Naesens M, Saez-Gimenez B, Vanaudenaerde BM, Vos R.   +8 more
europepmc   +1 more source

Targeting p38α in cancer: challenges, opportunities, and emerging strategies

Molecular Oncology, EarlyView.
p38α normally regulates cellular stress responses and homeostasis and suppresses malignant transformation. In cancer, however, p38α is co‐opted to drive context‐dependent proliferation and dissemination. p38α also supports key functions in cells of the tumor microenvironment, including fibroblasts, myeloid cells, and T lymphocytes.
Angel R. Nebreda
wiley   +1 more source

Stiff-Types

JCR: Journal of Clinical Rheumatology, 2019
openaire   +3 more sources